Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CYDYNASDAQ:NAMSNASDAQ:NGMNASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYDYCytoDyn$0.34+3.7%$0.28$0.10▼$0.49$405.66M1.153.49 million shs2.53 million shsNAMSNewAmsterdam Pharma$17.31+1.8%$18.19$14.06▼$27.29$1.90B0.01641,002 shs539,457 shsNGMNGM Biopharmaceuticals$1.54$1.55$0.60▼$4.69$128.53M1.271.47 million shsN/AOVIDOvid Therapeutics$0.29-0.2%$0.31$0.24▼$3.31$20.68M0.27472,063 shs809,763 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYDYCytoDyn+3.69%-6.07%+46.65%+19.23%+12.47%NAMSNewAmsterdam Pharma+1.76%-6.48%-2.92%-17.22%-10.82%NGMNGM Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%OVIDOvid Therapeutics-0.21%+1.79%-16.91%-45.27%-90.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYDYCytoDyn0.1195 of 5 stars0.03.00.00.01.10.00.0NAMSNewAmsterdam Pharma2.4875 of 5 stars3.51.00.00.02.25.00.0NGMNGM BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AOVIDOvid Therapeutics4.1102 of 5 stars3.52.00.04.62.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYDYCytoDyn 0.00N/AN/AN/ANAMSNewAmsterdam Pharma 3.00Buy$43.00148.41% UpsideNGMNGM Biopharmaceuticals 0.00N/AN/AN/AOVIDOvid Therapeutics 3.00Buy$2.78857.13% UpsideCurrent Analyst Ratings BreakdownLatest CYDY, NAMS, OVID, and NGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025OVIDOvid TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.00 ➝ $1.505/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $40.004/24/2025OVIDOvid TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/24/2025OVIDOvid TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.003/12/2025OVIDOvid TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $3.003/3/2025NAMSNewAmsterdam PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$41.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYDYCytoDyn$270K1,557.87N/AN/A($0.11) per share-3.07NAMSNewAmsterdam Pharma$47.14M40.33N/AN/A$3.50 per share4.95NGMNGM Biopharmaceuticals$4.42M29.10N/AN/A$1.80 per share0.86OVIDOvid Therapeutics$548K37.74N/AN/A$1.24 per share0.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYDYCytoDyn-$49.84M-$0.01N/A∞N/AN/AN/A-76.70%8/13/2025 (Estimated)NAMSNewAmsterdam Pharma-$176.94M-$1.88N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)NGMNGM Biopharmaceuticals-$142.38M-$1.72N/AN/AN/A-3,223.34%-77.85%-67.76%N/AOVIDOvid Therapeutics-$52.34M-$0.35N/AN/AN/A-5,142.56%-39.24%-26.19%8/12/2025 (Estimated)Latest CYDY, NAMS, OVID, and NGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025OVIDOvid Therapeutics-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million3/11/2025Q4 2024OVIDOvid Therapeutics-$0.16-$0.13+$0.03-$0.13$0.19 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYDYCytoDynN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ANGMNGM BiopharmaceuticalsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYDYCytoDynN/A0.350.35NAMSNewAmsterdam PharmaN/A10.6110.61NGMNGM BiopharmaceuticalsN/A7.797.79OVIDOvid Therapeutics0.185.665.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYDYCytoDyn5.06%NAMSNewAmsterdam Pharma89.89%NGMNGM Biopharmaceuticals75.74%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipCYDYCytoDyn0.54%NAMSNewAmsterdam Pharma20.84%NGMNGM Biopharmaceuticals35.90%OVIDOvid Therapeutics13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYDYCytoDyn201.25 billion1.22 billionNot OptionableNAMSNewAmsterdam Pharma4109.82 million74.37 millionOptionableNGMNGM Biopharmaceuticals13883.46 million53.50 millionOptionableOVIDOvid Therapeutics6071.11 million61.57 millionOptionableCYDY, NAMS, OVID, and NGM HeadlinesRecent News About These CompaniesHC Wainwright Issues Pessimistic Forecast for Ovid Therapeutics (NASDAQ:OVID) Stock PriceMay 29 at 1:15 AM | americanbankingnews.comOvid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from AnalystsMay 22, 2025 | americanbankingnews.comWhat is B. Riley's Estimate for OVID Q2 Earnings?May 20, 2025 | americanbankingnews.comOvid Therapeutics (NASDAQ:OVID) vs. Global Future City (OTCMKTS:FTCY) Financial AnalysisMay 19, 2025 | americanbankingnews.comOvid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comOvid Therapeutics Reports Business Updates and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comPhoreMost makes key appointments to Board to advance development of next-generation degrader therapeuticsMay 8, 2025 | cambridgenetwork.co.ukOvid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 6, 2025 | zacks.comOvid Police Chief, city accused of civil rights violationsApril 24, 2025 | msn.comOvid Therapeutics (OVID) Receives a Buy from TD CowenApril 23, 2025 | theglobeandmail.comBiotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA CutsApril 10, 2025 | biospace.comOvid's Main Street Business Owners Are Speaking Out About Recovery Process After January FireApril 5, 2025 | weny.comOvid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | markets.businessinsider.comNozzolio and NextEra to visit Ovid for donation event after Main Street fireApril 2, 2025 | fingerlakes1.comOvid Therapeutics price target lowered to $2 from $3 at H.C. WainwrightMarch 25, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $4 from $5 at BTIGMarch 25, 2025 | markets.businessinsider.comOvid man arrested for failing to register as sex offenderMarch 21, 2025 | fingerlakes1.comOvid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 12, 2025 | finance.yahoo.comWilliam Blair Sticks to Their Buy Rating for Ovid Therapeutics (OVID)March 12, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $3 from $4 at WedbushMarch 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumTop 4 ETFs for China Exposure After Tariff Relief By Nathan Reiff | May 17, 2025View Top 4 ETFs for China Exposure After Tariff Relief These ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsBuild a Complete Bond Portfolio With These 4 ETFsBy Nathan Reiff | May 17, 2025View Build a Complete Bond Portfolio With These 4 ETFsCYDY, NAMS, OVID, and NGM Company DescriptionsCytoDyn OTCMKTS:CYDY$0.34 +0.01 (+3.69%) As of 05/28/2025 03:59 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.NewAmsterdam Pharma NASDAQ:NAMS$17.31 +0.30 (+1.76%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$17.31 0.00 (-0.01%) As of 05/28/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.NGM Biopharmaceuticals NASDAQ:NGMNGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.Ovid Therapeutics NASDAQ:OVID$0.29 0.00 (-0.21%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.30 +0.01 (+4.20%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
